EloraTZP cut body weight by up to 23.3% and A1C by up to 2.9% at 48 weeks vs 14.8% and 2.4% with tirzepatide 15 mg in a phase 2b trial.
News|Videos|October 2, 2026
8 Endocrinology Headlines You Missed in September 2026
Author(s)Ryan Livingston
Fact checked by: Chelsie Derman
Stay up-to-date with the latest in FDA decisions, trial readouts, and key clinician insights from all corners of endocrinology.
Advertisement
Advertisement
Endocrinology saw some significant advancements over the last 30 days, with key approvals from the
Related to this article
Newly published results from the TRIUMPH-1 study have indicated the direct correlation between the triple agonist and several improvements to weight.
Real-world COMPETE SWITCH CV data at EASD 2026 linked semaglutide 2 mg escalation to 6% lower MACE risk vs switching to tirzepatide in T2D.
Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.
As drinking declines, Stevan Gonzalez, MD, Frances Lee, MD, and Brian Lee, MD, on the lingering burden of alcohol-associated liver disease.
FDA novel drug approvals in Q3 2026: 22 new therapies, including enlicitide, daraxonrasib, oveporexton, and first treatments for rare diseases.
Heavy drinking rose >36% since 2018 among middle-aged adults. A hepatologist on screening, sex-specific thresholds, and pandemic effects.
Preview the biggest anticipated FDA decisions of Q4 2026, including bepirovirsen for CHB, obinutuzumab for pMN, bezuclastinib for systemic mastocytosis, and more.
Advertisement
Advertisement